NUFORMIX PLC

• ⚠

  Material uncertainty over going concern

  We draw attention to note 1 in the financial statements, which indicates that there is a significant threat to the going concern status of the group. Cash held at the balance sheet date of £97k (2024: £20k) is therefore not sufficient and poses a going concern threat. The group is currently relying on a single product, NXP002, for its long-term future sustainable financial success. The loss was £653k for the year ended 30 September 2025 (2024: Loss of £3,641k). Accumulated losses at the balance sheet date of £10,462k (2024: £9,844k). The group successfully secured an additional £228k through fundraising in November 2025 however, this will not be sufficient to secure 12 months of operational activity.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +382.7%

  £20,210 → £97,550

• Net assets

  +5.5%

  £715,571 → £754,934

• Employees

  0%

  3 → 3

• Operating profit

  +81.9%

  -£3,647,053 → -£660,569

• Profit before tax

  +81.9%

  -£3,647,053 → -£660,569

• Wages

  0%

  £90,000 → £90,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. NUFORMIX PLC 2017-10-13 → present
2. LEVRETT PLC 2015-06-10 → 2017-10-13

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Kreston Reeves Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 1 in the financial statements, which indicates that there is a significant threat to the going concern status of the group. Cash held at the balance sheet date of £97k (2024: £20k) is therefore not sufficient and poses a going concern threat. The group is currently relying on a single product, NXP002, for its long-term future sustainable financial success. The loss was £653k for the year ended 30 September 2025 (2024: Loss of £3,641k). Accumulated losses at the balance sheet date of £10,462k (2024: £9,844k). The group successfully secured an additional £228k through fundraising in November 2025 however, this will not be sufficient to secure 12 months of operational activity.”

Group structure

1. NUFORMIX PLC · parent
   1. Nuformix Technologies Limited 100% · United Kingdom · pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing

Significant events

• “Post period end, on 11 November 2025, an Open Offer was completed. The Open Offer, underwritten by CMC Markets, raised £228,081 (before expenses) through the issue of 114,040,535 Open Offer Shares at an Issue Price of 0.2p per Share, including a share premium of £114,041.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

8

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.